About This Fund
Invivo Ventures III is the third venture capital fund from Invivo Partners, a Barcelona-based life sciences investor and one of Spain's leading venture capital managers focused on transformative healthcare and biotechnology innovation. The fund targets a final size of EUR 100 million and invests in early-stage European life sciences companies developing breakthrough technologies across cell and gene therapy, synthetic biology, artificial intelligence-enabled drug discovery, and advanced medical devices.
Registered with Spain's CNMV (Comision Nacional del Mercado de Valores) as Invivo Ventures III, FCRE (Fondo de Capital Riesgo Europeo), the fund continues the investment philosophy established in its predecessor funds—backing pre-seed and seed-stage spinouts and startups that address unmet medical needs through novel science and technology platforms. The fund typically leads or co-leads initial rounds, writing tickets from EUR 1 million to EUR 5 million, and maintains active portfolio support through Invivo's network of scientific advisors, clinical development experts, and corporate partners.
The fund's institutional investor base includes the European Investment Fund (EIF), Fond-ICO Global, the Catalan Institute of Finance (ICF, which committed EUR 8 million expandable to EUR 10 million), the Valencian Institute of Finance, and Barcelona City Council. This blend of development finance institutions and regional public investors reflects the fund's role as a cornerstone vehicle for Spain's emerging life sciences ecosystem, particularly within the biotechnology cluster anchored in Catalonia and Valencia. Portfolio companies from prior Invivo funds include biotech ventures such as Peptomyc, NEUmiRNA, and Signadori Bio.